The novel finding of the study was that LESW therapy improved hepatic fibrosis, hepatic function, and hepatic angiogenesis, accompanied by down-regulation of TGF-β1 and up-regulation of angiogenic factors such as bFGF and VEGF-B. The gene discussed is FGF2; the disease is Hepatic fibrosis.